TheraRadar
← Back
Data updated: Jun 28, 2026

PHARMACHEMIE BV

Generics

PHARMACHEMIE BV is a generic drug manufacturer focused on Oncology, Immunology.

1990
Since
6
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

PHARMACHEMIE BV's Key Drugs

PHARMACHEMIE BV's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHARMACHEMIE BV's Recent FDA Approvals

New NDA/BLA approvals for PHARMACHEMIE BV over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARMACHEMIE BV's Therapeutic Areas

PHARMACHEMIE BV's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 75%
3 drugs
Immunology 25%
1 drugs

PHARMACHEMIE BV's Top Competitors

PHARMACHEMIE BV's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PHARMACHEMIE BV Pipeline Snapshot

Active clinical trials for PHARMACHEMIE BV across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling